Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.95 |
| ▸ | CA2 | P00918 | 4/20 | 0.95 |
| ▸ | CA12 | O43570 | 3/20 | 0.95 |
| ▸ | CA7 | P43166 | 3/20 | 0.95 |
| ▸ | CA9 | Q16790 | 3/20 | 0.95 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.95 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.95 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KDR | P35968 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | TNF | P01375 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gentisic Acid SCHEMBL8084110 | 0.98 | CA1 (0.91) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL3690 | 0.98 | CA1 (1.00) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL29349919 | 0.98 | CA1 (1.00) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL30233582 | 0.98 | CA1 (1.00) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL2053863 | 0.98 | CA1 (1.00) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL10980548 | 0.95 | CA1 (0.95) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL455606 | 0.95 | CA1 (0.95) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL10975219 | 0.95 | CA1 (0.95) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL344389 | 0.95 | CA1 (0.95) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL10978035 | 0.95 | CA1 (0.95) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111712265-B | Diagnostic composition for PET imaging, method for producing the same and use thereof in diagnosis | AC免疫有限公司 | 2024-02-09 | — | — | CN | claimed |
| US-20210179975-A1 | COMPOSITION CONTAINING LANTHANIDE METAL COMPLEX | SPECIALTY OPERATIONS FRANCE (FR) | 2021-06-17 | — | — | US | claimed |
| EP-3743115-A1 | DIAGNOSTIC COMPOSITIONS FOR PET IMAGING, A METHOD FOR MANUFACTURING THE DIAGNOSTIC COMPOSITION AND ITS USE IN DIAGNOSTICS | AC Immune SA (CH) | 2020-12-02 | — | — | EP | claimed |
| WO-2019145293-A1 | DIAGNOSTIC COMPOSITIONS FOR PET IMAGING, A METHOD FOR MANUFACTURING THE DIAGNOSTIC COMPOSITION AND ITS USE IN DIAGNOSTICS | AC IMMUNE SA (CH) | 2019-08-01 | — | — | WO | claimed |
| US-20190169667-A1 | METHODS OF DECREASING TRISULFIDE BONDS DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | GENENTECH, INC. (US) | 2019-06-06 | — | — | US | claimed |
| EP-3455364-A2 | METHODS OF DECREASING TRISULFIDE BONDS DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | H. Hoffnabb-La Roche Ag (CH) | 2019-03-20 | — | — | EP | claimed |
| WO-2017196902-A2 | METHODS OF DECREASING TRISULFIDE BONDS DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | GENENTECH, INC. (US) | 2017-11-16 | — | — | WO | claimed |
| US-12616738-B2 | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid | NOVO NORDISK A/S (DK) | 2026-05-05 | — | — | US | disclosed |
| US-20260008997-A1 | CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION | GENENTECH, INC. (US) | 2026-01-08 | — | — | US | disclosed |
| EP-2970875-B2 | CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION | HOFFMANN LA ROCHE (CH) | 2025-11-26 | — | — | EP | disclosed |
| US-20250186600-A1 | EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS | COMERA LIFE SCIENCES, INC. | 2025-06-12 | — | — | US | disclosed |
| WO-2024036372-A1 | FORMULATIONS FOR RADIOTHERAPY AND DIAGNOSTIC IMAGING AND USE THEREOF IN TREATMENT, DIAGNOSIS AND IMAGING DISEASES | Clarity Pharmaceuticals Limited (AU) | 2024-02-22 | — | — | WO | disclosed |
| EP-4324482-A2 | EXCIPIENT COMPOUNDS FOR BIOPOLYMER FORMULATIONS | Comera Life Sciences, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| US-4470980-A | Method of increasing oral absorption of β-lactam antibiotics | INTERX RESEARCH CORP. (US) | 1984-09-11 | — | — | US | disclosed |
| US-4464363-A | HYDROXY ARYL- OR HYDROXY ARALKYL ACIDS OR SALTS | MERCK & CO., INC. (US) | 1984-08-07 | — | — | US | disclosed |
| US-4406896-A | ANTIBIOTICS, ACIDS, HYDROXY | MERCK & CO., INC. (US) | 1983-09-27 | — | — | US | disclosed |
| EP-0036534-A1 | An orally administrable drug form comprising a beta-lactam antibiotic and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-30 | — | — | EP | disclosed |
| EP-0036145-A1 | An orally administered drug form comprising a polar bioactive agent and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-23 | — | — | EP | disclosed |
| EP-0035770-A2 | An orally administered drug form comprising a glycosidic antibiotic and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-16 | — | — | EP | disclosed |
| EP-0031561-A2 | A rectally administered suppository comprising a drug and an adjuvant | MERCK & CO. INC. (US) | 1981-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616738-B2 | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid | SLC5A1, GLP1R, SLC5A2 | CA1 1173/4885CA2 335/4885CA12 1815/4885 |
| US-20260008997-A1 | CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION | CD99, BHMT, PROC | CA1 168/4885CA2 349/4885CA12 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.